| mRNA decay of most Arabidopsis miRNA targets requires slicer activity of AGO1 L Arribas-Hernández, LJ Kielpinski, P Brodersen Plant physiology 171 (4), 2620-2632, 2016 | 65 | 2016 |
| SHAPE Selection (SHAPES) enrich for RNA structure signal in SHAPE sequencing-based probing data LD Poulsen, LJ Kielpinski, SR Salama, A Krogh, J Vinther Rna 21 (5), 1042-1052, 2015 | 64 | 2015 |
| Massive parallel-sequencing-based hydroxyl radical probing of RNA accessibility LJ Kielpinski, J Vinther Nucleic acids research 42 (8), e70-e70, 2014 | 60 | 2014 |
| RNase H sequence preferences influence antisense oligonucleotide efficiency ŁJ Kiełpiński, PH Hagedorn, M Lindow, J Vinther Nucleic acids research 45 (22), 12932-12944, 2017 | 57 | 2017 |
| AntimiR targeting of microRNA-134 reduces seizures in a mouse model of Angelman syndrome A Campbell, G Morris, A Sanfeliu, J Augusto, E Langa, JC Kesavan, ... Molecular Therapy-Nucleic Acids 28, 514-529, 2022 | 18 | 2022 |
| Detection of reverse transcriptase termination sites using cDNA ligation and massive parallel sequencing LJ Kielpinski, M Boyd, A Sandelin, J Vinther Deep Sequencing Data Analysis, 213-231, 2013 | 13 | 2013 |
| Body fluid identification of blood, saliva and semen using second generation sequencing of micro-RNA CH Petersen, BB Hjort, T Tvedebrink, LJ Kielpinski, J Vinther, N Morling Forensic Science International: Genetics Supplement Series 4 (1), e204-e205, 2013 | 11 | 2013 |
| Reproducible analysis of sequencing-based RNA structure probing data with user-friendly tools LJ Kielpinski, N Sidiropoulos, J Vinther Methods in enzymology 558, 153-180, 2015 | 10 | 2015 |
| Characterization of Escherichia coli RNase H Discrimination of DNA Phosphorothioate Stereoisomers ŁJ Kiełpiński, ED Funder, S Schmidt, PH Hagedorn nucleic acid therapeutics 31 (6), 383-391, 2021 | 5 | 2021 |
| Investigating discovery strategies and pharmacological properties of stereodefined phosphorodithioate LNA gapmers J Duschmalé, A Schäublin, E Funder, S Schmidt, ŁJ Kiełpiński, H Nymark, ... Molecular Therapy-Nucleic Acids 29, 176-188, 2022 | 2 | 2022 |
| Antisense Oligonucleotides Targeting ATXN3 HR Hudlebusch, L Pedersen, E Funder, L Kielpinski, C Sondergaard, ... US Patent App. 17/540,495, 2023 | 1 | 2023 |
| Oligonucleotides for modulating TMEM106B expression P Hagedorn, ML Jensen, L Kielpinski, A Easton, B Chih US Patent 11,485,975, 2022 | 1 | 2022 |
| Therapeutic oligonucleotides capture and detection MA Jensen, L Joenson, L Kielpinski, M Lindow, J Vikesaa | 1 | 2019 |
| RNase H sequence preferences influence antisense oligonucleotide efficiency LJ Kielpinski, PH Hagedorn, M Lindow, J Vinther NUCLEIC ACIDS RESEARCH 47 (5), 2701-2701, 2019 | 1 | 2019 |
| Antisense oligonucleotides for modulating tmem106b expression A Easton, H Gylling, D Hansen, L Kielpinski, D Mellal, H Nymark, B Chih, ... US Patent App. 18/777,933, 2024 | | 2024 |
| Oligonucleotides for Modulating Apolipoprotein E4 Expression H Nymark, L Pedersen, FOO Lynette, AM HOEG, L Kielpinski US Patent App. 18/652,148, 2024 | | 2024 |
| Therapeutically targeting the classical complement pathway with antisense oligonucleotides in Alzheimer′ s disease Y Wang, T Wu, A Gogineni, MC Tsai, L Kielpinski, A Mahajan, S Pandey, ... bioRxiv, 2024.08. 23.609240, 2024 | | 2024 |
| Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same A Munk, HM Gylling, JE Hanson, LJ Kielpinski US Patent App. 18/054,115, 2023 | | 2023 |
| Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same A Munk, HM Gylling, JE Hanson, LJ Kielpinski US Patent App. 18/054,113, 2023 | | 2023 |
| Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same A Munk, HM Gylling, JE Hanson, LJ Kielpinski US Patent App. 18/054,116, 2023 | | 2023 |
